Key Drivers
- Strong Cash Flow
- Moderate Leverage
- Rich Valuation
AIAI Summary
ZBH should be viewed less as a cheap orthopedic turnaround and more as a mature, cash-generative med-tech platform where upside depends on sustained margin execution, buybacks, and proving robotics/innovation can close the competitive gap, while FDA/timing and integration missteps remain the main risks to any re-rating.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Moderate Leverage
- •Rich Valuation
ZBH shows solid margins and strong cash generation, but meaningful leverage, a thin tangible asset base, and a premium valuation temper overall attractiveness.
Price Behavior
Key Price Behavior Insights:
- •Choppy Uptrend
- •Mid-80s Support
- •Low-90s Resistance
ZBH has drifted higher over the last month but remains choppy, with support near $84 and resistance in the low $90s after a sharp pullback cooled momentum.
Sharp reversal from $93.10 to $84.17 showed momentum faded quickly
Sentiment & News
Key News Insights:
- •Value-stock strength
- •Margin expansion
- •Growth investments
Zimmer Biomet is gaining value-stock support on strong cash flow and margin gains, while acquisitions and a new India tech center add long-term growth optionality despite lagging robotic-surgery innovators.
The headlines are modestly bullish, suggesting ZBH's valuation and operational improvements are being reinforced by strategic expansion, though innovation gaps versus peers remain a watch point
Similar Companies in Healthcare
Other companies in the same sector with AI ratings